Breakout Bulletin: May 31-June 5

You’re busy. Between patients, prior authorizations, inbox messages, and everything else on your plate, keeping up with the literature is the first thing that slips. Dermatology Times NP/PA Connect is here to make sure it doesn’t. Each week, we pull the most clinically relevant news from across dermatology and bring it straight to your inbox — what’s new, what it means, and what’s worth watching. This week: a CAR T therapy showing durable remission in dermatomyositis without ongoing immunosuppression, a rare BCC syndrome finally getting a registrational trial, the first IND ever filed for peeling skin syndrome, new practice guidance on a frequently missed manifestation of psoriasis, and an early-phase AD topical worth watching — with some caveats.

CAR T Therapy Shows Durable Drug-Free Remission in Dermatomyositis

New data from the phase 1/2 RESET-Myositis trial, presented at the EULAR 2026 Congress in London, show that rese-cel — Cabaletta Bio’s autologous CD19-targeting CAR T therapy — produced durable, immunomodulator-free responses in patients with dermatomyositis and antisynthetase syndrome.¹

Among 6 patients with dermatomyositis, 83% achieved an immunomodulator-free moderate to major Total Improvement Score response at 16 weeks. All 5 of those patients maintained that response through their latest follow-up, with durations up to 1.5 years. Among patients with antisynthetase syndrome, 75% reached the same threshold at 16 weeks. The first patient with juvenile dermatomyositis treated with rese-cel achieved a moderate TIS response at 16 weeks, maintained through 32 weeks.

The safety signal across all 17 myositis patients was favorable: 100% experienced either no cytokine release syndrome or transient Grade 1 CRS only, and no ICANS of any grade was observed. Cabaletta reports that 80% of phase 1/2 DM and antisynthetase syndrome patients would have met the primary endpoint of the planned registrational cohort, with topline data anticipated in mid-2027.

SSc and lupus cohorts are also showing signal. In RESET-SSc, 83% of evaluable patients achieved rCRISS-25 at 36 weeks off all immunomodulators, with a median 7.5% improvement in percent predicted FVC in patients with ILD at screening. In RESET-SLE, 75% of patients with 12 months of follow-up achieved DORIS remission off immunomodulators for the full duration.

MORE ON DRUG WATCH

“Over 80% of the phase 1/2 dermatomyositis patients would have achieved the pivotal primary endpoint and all five of these patients maintained their response through the latest follow-up as long as 1.5 years.” — David J. Chang, MD, Chief Medical Officer, Cabaletta Bio

▶ Why it matters: Durable drug-free remission in DM is a meaningful threshold that existing therapies rarely achieve. This is early-phase data, but the durability signal and safety profile are both worth tracking as the registrational cohort enrolls.

A Lesion-Directed BCC Therapy Is Entering Registrational Development for Gorlin Syndrome

Medicus Pharma has submitted a phase 2b study protocol to the FDA under its existing IND for SkinJect, a doxorubicin microneedle array, with the goal of generating data to support a New Drug Application in Gorlin syndrome — a rare inherited disorder characterized by lifelong development of multiple basal cell carcinomas.²

The planned SKNJCT-005 study will enroll up to 50 patients with Gorlin syndrome who have multiple BCC lesions, treating 2 to 4 target lesions simultaneously. The primary endpoint is complete clinical clearance in at least 50% of prospectively selected target lesions by week 10, with follow-up through week 24 to assess durability. The protocol includes blinded independent central review with reflectance confocal microscopy and line-field OCT.

MORE ON RARE DISEASES

The submission builds on phase 2 data from the SKNJCT-003 study in nodular BCC, where the 200 µg cohort achieved 64% clinical clearance and 55% histological clearance at day 57 with no treatment-related serious adverse events. There are currently no FDA-approved lesion-directed therapies specifically developed for Gorlin syndrome. Medicus has applied for Orphan Drug Designation and plans to seek a Rare Pediatric Disease Priority Review Voucher given the condition’s onset in childhood or adolescence.

▶ Why it matters: Patients with Gorlin syndrome face lifelong surgical burden from continuous BCC development. A validated topical alternative that can treat multiple lesions simultaneously would represent a meaningful shift in how this condition is managed.

A Practical Roadmap for Genital Psoriasis — A Manifestation Most Clinicians Miss

A new consensus manuscript from the Genital Psoriasis Wellness Consortium, published in the American Journal of Clinical Dermatology, provides age-stratified guidance for clinicians managing genital psoriasis — a manifestation that affects more than 60% of patients with psoriasis at some point in their disease course but is routinely underdiagnosed.³

Developed through a modified Delphi process requiring ≥75% expert agreement, the guidance addresses four clinical areas: routine genital assessment as part of comprehensive skin exams; verbal consent, chaperone protocols, and stigma-reducing communication; age-specific treatment considerations across pediatric, adult, and older patient populations; and minimization of long-term topical corticosteroid use given the anatomical sensitivity of genital skin.

MORE ON PSORIASIS

The authors frame this explicitly as a call to action. The diagnosis gap is attributed to both clinician behavior — routine genital assessment is not universally practiced — and patient reluctance to raise the topic. Genital psoriasis has been associated with sexual dysfunction, psychological distress, and reduced treatment adherence.

“Genital psoriasis is one of the most impactful, yet consistently overlooked, manifestations of psoriatic disease. Our consensus work represents a ‘call to action’ — giving clinicians a comprehensive, age-specific roadmap to approach genital psoriasis with the same rigor they bring to every other aspect of dermatologic care.” — Michael J. Payette, MD, MBA, FAAD, Central Connecticut Dermatology / UConn Health

▶ Why it matters: APPs are often the clinician conducting the full skin exam. Normalizing routine genital assessment and knowing what to do when you find it are both within scope — and this guidance gives you the framework.

The First IND for Peeling Skin Syndrome Has Been Filed

Quoin Pharmaceuticals has submitted the first Investigational New Drug application ever filed specifically for peeling skin syndrome, a rare autosomal recessive genodermatosis caused by loss-of-function variants in the CDSN gene characterized by excessive epidermal shedding, severe pain, and chronic pruritus — with no approved treatment or cure.⁴

The IND covers QRX003, a topical broad-spectrum serine protease inhibitor already under development for Netherton syndrome. Initial data from a single pediatric patient in an ongoing investigator-led study showed substantial reductions in modified IASI, IGA, and CDLQI after 12 weeks of treatment. The patient has continued therapy for more than 15 months with no adverse events.

Quoin plans to initiate a phase 2 study in the second half of 2026, enrolling 6 to 8 pediatric and adult participants in the US and Europe. QRX003 received FDA Fast Track designation for Netherton syndrome in March 2026.

▶ Why it matters: For APPs who encounter rare genodermatoses in tertiary or academic settings, IND submission is the critical first step toward a controlled trial. PSS has had no regulatory development activity until now.

An Antiseptic Topical Shows Early Signal in AD

Turn Therapeutics reported interim findings from the first 50 subjects in its phase 2 trial of GX-03, a topical extended-release polyhexanide formulation, in moderate to severe atopic dermatitis. At week 4, 92.6% of subjects in the GX-03 arm achieved EASI-50 versus 65.2% in the vehicle arm. EASI-90 rates at week 8 were 51.9% versus 34.8%.⁵

No treatment-related serious adverse events, tolerability concerns, or discontinuations were reported during the interim period. GX-03’s mechanism differs from approved immunomodulatory therapies for AD — it is an antiseptic compound positioned to act within the skin microenvironment, though the precise mechanism in AD has not been fully characterized in regulatory-grade published data.

The vehicle response rates in this trial are worth noting: a 65.2% EASI-50 rate at 4 weeks is substantially higher than the 30% to 45% range typically observed in placebo arms of AD trials. The company acknowledged this and has refined enrollment criteria for the second stage of the trial, focusing on baseline EASI scores and body surface area involvement.5 The adaptive protocol adjustment is methodologically sound, but the elevated vehicle response limits how much weight to give the separation between arms at this stage.

▶ Why it matters: Worth watching, not yet acting on. The early EASI-50 signal is interesting and the safety profile is clean, but the vehicle response inflation makes meaningful interpretation of the gap difficult until stage 2 data arrive.

RECENT AD NEWS

References

1. Cabaletta Bio announces new rese-cel data and development updates across autoimmune portfolio, including encouraging early PC-free lupus findings, at EULAR 2026 Congress. News release. Cabaletta Bio. June 3, 2026. Accessed June 4, 2026. https://www.cabalettabio.com/news-media/press-releases/detail/149/cabaletta-bio-announces-new-rese-cel-data-and-development

2. Medicus Pharma Advances SkinJect® into registrational development for Gorlin Syndrome. News release. Globe Newswire. Published June 3, 2026. Accessed June 4, 2026. https://www.globenewswire.com/news-release/2026/06/03/3305990/0/en/medicus-pharma-advances-skinject-into-registrational-development-for-gorlin-syndrome.html?_gl=1*42bpxa*_up*MQ..*_ga*MTQxNTk5Mzk2NS4xNzgwNDkxNjUy*_ga_B6167QB2TF*czE3ODA0OTE2NTIkbzEkZzAkdDE3ODA0OTE2NTIkajYwJGwwJGgyMDgwMDU3NDc3*_ga_ERWPGTJ5X8*czE3ODA0OTE2NTIkbzEkZzAkdDE3ODA0OTE2NTIkajYwJGwwJGgw

3. New expert consensus provides age-specific guidance for improving care for individuals with genital psoriasis published in the American Journal of Clinical Dermatology. News release. Arcutis Biotherapeutics. Published June 3, 2026. Accessed June 4, 2026. https://www.globenewswire.com/news-release/2026/06/03/3305996/0/en/new-expert-consensus-provides-age-specific-guidance-for-improving-care-for-individuals-with-genital-psoriasis-published-in-the-american-journal-of-clinical-dermatology.html?_gl=1*42bpxa*_up*MQ..*_ga*MTQxNTk5Mzk2NS4xNzgwNDkxNjUy*_ga_B6167QB2TF*czE3ODA0OTE2NTIkbzEkZzAkdDE3ODA0OTE2NTIkajYwJGwwJGgyMDgwMDU3NDc3*_ga_ERWPGTJ5X8*czE3ODA0OTE2NTIkbzEkZzAkdDE3ODA0OTE2NTIkajYwJGwwJGgw

4. Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome. News release. Globe Newswire. June 2, 2026. Accessed June 4, 2026. https://www.globenewswire.com/news-release/2026/06/02/3305172/0/en/quoin-pharmaceuticals-submits-ind-application-for-qrx003-in-peeling-skin-syndrome.html

5. Turn Therapeutics reports interim analysis findings and adaptive optimization strategy from phase 2 GX-03 trial in moderate-to-severe atopic dermatitis. News release. Turn Therapeutics. Published June 1, 2026. Accessed June 4, 2026. https://www.businesswire.com/news/home/20260601276401/en/Turn-Therapeutics-Reports-Interim-Analysis-Findings-and-Adaptive-Optimization-Strategy-from-Phase-2-GX-03-Trial-in-Moderate-to-Severe-Atopic-Dermatitis